Galectin Role in Periodontal Disease

This study aimed at exploring the effect of nonsurgical periodontal treatment on galectin 1 and 3 GCF levels in patients having gingivitis, periodontitis stage III compared to periodontally healthy individuals and if galectin-1 and -3 could serve as diagnostic markers and/or therapeutic targets for periodontitis, in addition to revealing their possible role in the periodontal disease. 45 systemically healthy participants were enrolled in this investigation, equally subdivided into three groups of 15 patients each: gingivitis, periodontitis (stage III) and control group with healthy gingiva. Probing depth, clinical attachment level, gingival and plaque index were registered. GCF levels of galectin-1 and -3 were evaluated in all included groups (before and after non-surgical treatment for periodontitis group) using enzyme linked immune-sorbent assay (ELISA) kit.

an average of about 10 months to assess level of gal-1 & -3 after collection of GCF samples at baseline (1st appointment) for all groups and another sample collection after 4 weeks for group II after performing scaling and root planning

Inclusion Criteria: Non-smokers from both genders. Not suffering from systemic diseases, pregnancy/lactation. Not taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs before inclusion in the study by 6 months. Patients with only gingivitis or periodontitis stage III. Periodontitis patients who did not receive any professional periodontal treatment in the last 6 months. Exclusion Criteria: smokers. having systemic diseases, pregnancy/lactation. taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs in the past 6 months. Patients having periodontitis any other stage than stage III. Periodontitis patients who receive any professional periodontal treatment in the last 6 months.